Skip to main content
Medical information Clinical review pending

Genetic Testing

Factor II Mutation Screening F2 G20210A

Factor II Mutation Screening F2 G20210A is a genetic test to identify the G20210A mutation in the prothrombin gene, which is associated with an increased risk of blood clots. Confirm with the laboratory before booking.

General information only: This page is not a diagnosis or personal medical advice. A qualified clinician should decide whether testing is appropriate and interpret results in context.

Review status: No completed medical review is recorded for this page.

Ask a question
Counselor guidance included Confidential handling Kenya-wide coordination

At a glance

Plan your test

Sample
Peripheral blood sample (usually collected in an EDTA tube). Confirm specific requirements with the laboratory before booking.
Results
Confirm with the laboratory before booking.
Preparation
No special preparation is typically required for this test. Confirm with the laboratory before booking.
Test priceKSh 12,000

Payment: M-Pesa and card options can be confirmed during booking.

Insurance & government schemes

Is this test covered for you?

We help you verify whether the Factor II Mutation Screening F2 G20210A test can be claimed against your insurer, employer scheme or a Kenyan government health scheme — before you book. Coverage depends on your plan, clinical indication and your provider's rules; final approval always rests with them.

Talk to a claims advisor

Providers & schemes we can help you check

Government & public schemes

SHIF — Social Health Insurance Fund Linda Mama EduAfya NHIF (legacy cards)

Eligibility and benefits follow the current rules of the Social Health Authority (SHA) and applicable government programmes.

Private insurers & employer schemes

Jubilee Health AAR APA Britam CIC Madison Resolution Pioneer Minet Old Mutual GA Life Heritage + other licensed insurers

Names shown for identification only — listing does not imply partnership or guarantee of coverage.

Have these ready when we check

  • Insurer or scheme name & policy / member number
  • A clinician's request / prescription for the test
  • Pre-authorisation letter, if your plan requires one

Free coverage check

Ask us to verify your cover

Send your details and our claims team confirms what documents you need and whether pre-authorisation applies — usually the same working day.

+254

Used only to process your coverage check — see our Privacy Policy. Verification support is free and does not guarantee your provider will pay.

01

Start with fit

Is this the right test for you?

The best test starts with a clear clinical question. These are common reasons a clinician or family may consider this test.

  • ✓Personal or family history of venous thromboembolism (VTE)
  • ✓Unexplained blood clots
  • ✓Evaluation for recurrent pregnancy loss
  • ✓Individuals with known risk factors for thrombosis
  • ✓Pre-surgical assessment in high-risk patients
02

In plain language

What this test helps you understand

Identifies the G20210A mutation in the prothrombin gene, which is associated with an increased risk of thrombosis (blood clots). This information can aid in risk assessment and management strategies.
Factor II Mutation Screening F2 G20210A is a specialized genetic test used to identify a specific mutation in the prothrombin gene. This mutation, known as G20210A, is linked to an increased risk of developing abnormal blood clots, potentially leading to serious health issues like deep vein thrombosis (DVT) or pulmonary embolism (PE). Understanding your genetic predisposition through this test can help you make informed health decisions.

This test detects the presence of the G20210A mutation by analyzing a peripheral blood sample using the End Point PCR + RFLP method.

Individuals who might consider this test include those with a family history of clotting disorders, people who have experienced unexplained blood clots, patients being evaluated for recurrent miscarriages, and individuals with risk factors for thrombosis like obesity, smoking, or prolonged immobility.

Taking this test offers potential benefits such as early detection of increased clotting risk, guidance for personalized treatment plans to reduce thrombosis risk, and information for family planning.

Results will indicate whether the G20210A mutation is present. A positive result suggests an increased risk of thrombosis, while a negative result indicates the mutation was not detected. It is crucial to discuss your results with a healthcare professional to understand their implications and plan any necessary follow-up care.
03

Medical review status

Clinical review pending

A completed medical review is not recorded for this page. No clinician has endorsed the information shown here. Please discuss testing decisions with a qualified healthcare professional.

Meet the DNA Labs Kenya medical team →
04

A simple process

What happens next?

You do not have to navigate the test alone. We help you move from question to next step.

1

Speak with us

We check the test and answer your questions before collection.

2

Give your sample

Choose home collection or a coordinated hub visit in Kenya. We explain whether this test uses a cheek swab or blood draw.

3

Understand your report

A counselor helps you understand the result and the next steps.

05

Choose your collection

Home collection or a lab visit

We will explain the sample, preparation, and next steps before anything is collected.

Home collection

Choose a coordinated visit at home or another convenient location. Our team confirms the appointment and sample requirements in advance.

Lab or hub visit

Prefer to visit a coordinated location? We can guide you to the right hub and explain what to expect when you arrive.

Ask about locations →
PreparationNo special preparation is typically required for this test. Confirm with the laboratory before booking.
SamplePeripheral blood sample (usually collected in an EDTA tube). Confirm specific requirements with the laboratory before booking.
MethodologyEnd Point PCR + RFLP (Restriction Fragment Length Polymorphism).
PrivacyYour sample and report are handled confidentially. Ask the team how your information is stored and shared.
This test only detects the specific G20210A mutation in the prothrombin gene. It does not detect other genetic mutations associated with thrombosis. A negative result does not completely rule out an increased risk of clotting. Confirm with the laboratory before booking.
06

Read your report

What common result terms mean

PositiveA finding was identified. Your clinician or counselor will explain what it means for your care.
NegativeThe specific finding tested for was not identified. It does not rule out every possible cause.
VUSA variant was found, but current evidence is not enough to classify it. Your counselor can explain follow-up.
07

Questions people ask

Frequently asked questions

The Factor II mutation, specifically G20210A, is a change in the prothrombin gene. It can increase the likelihood of developing blood clots.
This test helps identify individuals at higher risk for blood clots, allowing for potential preventive measures and personalized medical care.
A positive result indicates the presence of the G20210A mutation, suggesting an increased risk of thrombosis. Discuss this with your doctor.
A negative result means the specific G20210A mutation was not detected. However, other factors can still influence clotting risk.
A sample of peripheral blood is typically collected for this test.
Generally, fasting is not required for this test, but please confirm with the laboratory before your appointment.
08

Collaboration

Open for partnership with hospitals, clinics, doctors & researchers

Whether you are referring patients, building a research programme or supporting students, we work as an extension of your team — with responsive communication and clear scientific standards.

Hospitals & clinics

Referral pathways, coordinated sample logistics and shared reporting that fits your clinical workflow.

Doctors & specialists

LOINC-coded reports, ACMG-based variant classification and a direct scientific line for complex cases.

Research institutions

Sanger sequencing, NGS panels and custom assays — with project design support, batch pricing and agreed turnaround commitments.

Students & academic projects

Discounted laboratory services for college, master's and PhD research projects — including proposal guidance and cost-effective batch testing.

Explore partnerships
09

Trust & transparency

Sources, standards & how this page is maintained

Standards & references

  • ACMG/AMP technical standards for sequence variant interpretation
  • ClinGen curation and gene–disease validity frameworks where applicable
  • LOINC-coded reporting for interoperable results
  • ISO 9001:2015 quality management; ISO 15189 accreditation in progress

Page provenance

  • Last updated: September 27, 2026
  • Medical review: not yet completed
  • Written for patients & clinicians in Kenya; reviewed periodically against current guidance

Medical disclaimer: this page is general information, not a diagnosis or personal medical advice. Testing decisions and result interpretation should be made with a qualified healthcare professional.

Keep exploring

Related tests

View all tests →
Chat on WhatsApp